Emerging Therapies in Neovascular Retinal Disease – Featuring Wheel of Knowledge

1.00 CME
$0 FEE


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Activity Description

Outcomes for patients with neovascular retinal disease have been revolutionized by the integration of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy into management protocols. However, approximately two-thirds of patients receive a suboptimal response to anti-VEGF therapy. For those who respond to treatment, the individualization of dosing schedules to maintain visual acuity gains can be challenging and burdensome to the patient. To further enhance visual outcomes and reduce treatment burden, there is a need to discover and classify novel molecular pathways for targeted therapeutic intervention as well as novel methods for sustained delivery. In this recorded satellite symposium, experts review the evidence regarding the long-term effectiveness of current treatments, assess the mechanisms of novel treatments that target alternate pathways as well as those that offer medication delivery for extended periods of time, and evaluate new findings for these novel therapies that may improve treatment for patients with neovascular retinal disease.

Target Audience

The intended audience for the activity is retina specialists, comprehensive ophthalmologists, and other health care professionals involved in the management of patients with neovascular retinal disease.

Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Assess current evidence regarding the long-term effectiveness of treatments for neovascular retinal disease.
  • Assess the mechanisms of novel treatments for neovascular retinal disease that target alternate pathways and those that offer medication delivery for extended periods of time.
  • Evaluate new findings about emerging therapies that may improve the treatment of neovascular retinal disease.

Activity Chair

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV


Peter A. Campochiaro, MD
George S. and Dolores D. Eccles 
Professor of Ophthalmology and Neuroscience 
Johns Hopkins University School of Medicine 
Baltimore, MD 

Charles C. Wykoff, MD, PhD
Retina Consultants of Houston
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 6, 2020, through February 5, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationship(s):

Peter A. Campochiaro, MD
Consulting Fee: AGTC, AsclepiX, Exonate, Graybug Vision, Merck, Novartis, Wave Life Sciences
Consulting Fee (Paid to Institution): Aerpio, Genentech/Roche
Contracted Research: Aerpio, Allegro, AsclepiX, Clearside, Genentech/Roche, Graybug Vision, Oxford Biomedica, Regeneron, Regenxbio, Sanofi Genzyme Ownership Interest: Allegro, Graybug Vision

Arshad M. Khanani, MD, MA
Consulting Fee: Aerpio, Alimera, Allergan, Genentech, Kodiak, Notal Vision, Novartis, Opthea, Orbit Biomedical, Oxurion, PolyPhotonix, Recens Medical, Regenxbio, Roche, Santen
Speakers Bureau: Allergan, Genentech, Novartis
Contracted Research: Adverum, Aerpio, Allergan, Clearside, Gemini Therapeutics, Genentech, Gyroscope, Kodiak, Novartis, Ophthotech, Opthea, Oxurion, Regenxbio, Roche

Charles C. Wykoff, MD, PhD
Consulting Fee: Adverum, Aerpio, Alimera, Allegro, Allergan, Apellis, Bayer, Clearside, Genentech, Kodiak, Novartis, Regeneron, Regenxbio, Roche
Speakers Bureau: Regeneron
Contracted Research: Adverum, Aerpio, Allergan, Apellis, Clearside, Genentech, Kodiak, Regeneron Regenxbio, Roche

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com